Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis

Cancer Letters

Volumn 287, Issue 2, 2010, Pages 224-230

  Jang, Ji Hoon ^a   Park, Jun Soo ^b   Lee, Tae Jin ^c   Kwon, Taeg Kyu ^a  

^a Keimyung University   (South Korea)

^b Sogang University   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

Author keywords

Apoptosis; c FLIP; Cystamine; TRAIL; Transglutaminase 2

Indexed keywords

CYSTAMINE; FLICE INHIBITORY PROTEIN; PROCASPASE 3; PROCASPASE 8; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KIDNEY CANCER; MESANGIUM CELL; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, RENAL CELL; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL LINE, TUMOR; CYSTAMINE; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HUMANS; KIDNEY NEOPLASMS; OLIGOPEPTIDES; RECOMBINANT PROTEINS; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TRANSGLUTAMINASES;

EID: 72949098051     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.013     Document Type: Article

References (29)

1. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
2. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
3. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5 (2005) 876-885
4. Ozoren N., Fisher M.J., Kim K., Liu C.X., Genin A., Shifman Y., Dicker D.T., Spinner N.B., Lisitsyn N.A., and El-Deiry W.S. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol. 16 (2000) 917-925
5. Wang S., and El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22 (2003) 8628-8633
6. Ivanov V.N., Bhoumik A., and Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 22 (2003) 3152-3161
7. Lesort M., Lee M., Tucholski J., and Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278 (2003) 3825-3830
8. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A., Egawa S., Ikeuchi T., Tanaka H., Nakano R., Tanaka K., Hozumi I., Inuzuka T., Takahashi H., and Tsuji S. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 18 (1998) 111-117
9. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., and Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8 (2002) 143-149
10. Dubinsky R., and Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Movement Disord. 21 (2006) 530-533
11. Akar U., Ozpolat B., Mehta K., Fok J., Kondo Y., and Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol. Cancer Res. 5 (2007) 241-249
12. Cao L., Petrusca D.N., Satpathy M., Nakshatri H., Petrache I., and Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29 (2008) 1893-1900
13. Yuan L., Siegel M., Choi K., Khosla C., Miller C.R., Jackson E.N., Piwnica-Worms D., and Rich K.M. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26 (2007) 2563-2573
14. Kim S., Lee T.J., Leem J., Choi K.S., Park J.W., and Kwon T.K. Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. J. Cell Biochem. 104 (2008) 895-907
15. Verma A., Wang H., Manavathi B., Fok J.Y., Mann A.P., Kumar R., and Mehta K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 66 (2006) 10525-10533
16. Fok J.Y., Ekmekcioglu S., and Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol. Cancer Ther. 5 (2006) 1493-1503
17. David E., Sinha R., Chen J., Sun S.Y., Kaufman J.L., and Lonial S. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin. Cancer Res. 14 (2008) 5090-5098
18. Sugamura K., Gibbs J.F., Belicha-Villanueva A., Andrews C., Repasky E.A., and Hylander B.L. Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts. Oncology 74 (2008) 188-197
19. Carter B.Z., Mak D.H., Schober W.D., Dietrich M.F., Pinilla C., Vassilev L.T., Reed J.C., and Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111 (2008) 3742-3750
20. Frew A.J., Lindemann R.K., Martin B.P., Clarke C.J., Sharkey J., Anthony D.A., Banks K.M., Haynes N.M., Gangatirkar P., Stanley K., Bolden J.E., Takeda K., Yagita H., Secrist J.P., Smyth M.J., and Johnstone R.W. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl. Acad. Sci. USA 105 (2008) 11317-11322
21. Hyer M.L., Croxton R., Krajewska M., Krajewski S., Kress C.L., Lu M., Suh N., Sporn M.B., Cryns V.L., Zapata J.M., and Reed J.C. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 65 (2005) 4799-4808
22. Palacios C., Yerbes R., and Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res. 66 (2006) 8858-8869
23. Mehta K., Fok J.Y., and Mangala L.S. Tissue transglutaminase: from biological glue to cell survival cues. Front. Biosci. 11 (2006) 173-185
24. Herman J.F., Mangala L.S., and Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25 (2006) 3049-3058
25. Antonyak M.A., Miller A.M., Jansen J.M., Boehm J.E., Balkman C.E., Wakshlag J.J., Page R.L., and Cerione R.A. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J. Biol. Chem. 279 (2004) 41461-41467
26. Kweon S.M., Lee Z.W., Yi S.J., Kim Y.M., Han J.A., Paik S.G., and Ha S.S. Protective role of tissue transglutaminase in the cell death induced by TNF-alpha in SH-SY5Y neuroblastoma cells. J. Biochem. Mol. Biol. 37 (2004) 185-191
27. Fesus L., Madi A., Balajthy Z., Nemes Z., and Szondy Z. Transglutaminase induction by various cell death and apoptosis pathways. Experientia 52 (1996) 942-949
28. Milakovic T., Tucholski J., McCoy E., and Johnson G.V. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J. Biol. Chem. 279 (2004) 8715-8722
29. Chen J.S., Konopleva M., Andreeff M., Multani A.S., Pathak S., and Mehta K. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J. Cell. Physiol. 200 (2004) 223-234